Hennion & Walsh Asset Management Inc. Has $2.31 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Hennion & Walsh Asset Management Inc. cut its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 2.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 98,629 shares of the biopharmaceutical company’s stock after selling 2,740 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in TG Therapeutics were worth $2,307,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of TG Therapeutics by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock worth $233,500,000 after acquiring an additional 199,770 shares in the last quarter. Opaleye Management Inc. boosted its stake in TG Therapeutics by 2.9% in the 1st quarter. Opaleye Management Inc. now owns 2,280,000 shares of the biopharmaceutical company’s stock worth $34,679,000 after purchasing an additional 65,000 shares during the period. Marshall Wace LLP bought a new position in TG Therapeutics during the 2nd quarter worth about $36,501,000. Hood River Capital Management LLC raised its stake in shares of TG Therapeutics by 6.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock valued at $27,982,000 after purchasing an additional 98,892 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in shares of TG Therapeutics in the second quarter valued at about $10,423,000. 58.58% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on TGTX shares. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a report on Wednesday, September 18th. Finally, The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $31.83.

TG Therapeutics Stock Performance

TGTX opened at $23.36 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The business has a fifty day simple moving average of $23.44 and a 200 day simple moving average of $19.63. TG Therapeutics, Inc. has a 1 year low of $6.89 and a 1 year high of $26.41. The company has a market capitalization of $3.61 billion, a PE ratio of 101.57 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. The company had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company’s revenue was up 357.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) earnings per share. Research analysts expect that TG Therapeutics, Inc. will post 0.13 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.